GLS4 were explored. The anti-HBV activity in the HepAD38 system, and cytotoxicity profiles of each of the new compounds has been assessed. Among them, five new iodo- and bromo-heteroarylpyrimidines analogs displayed anti-HBV activity in the low micromolar range.
探索了对先前报道的HBV衣壳装配效应子(如BAY 41-4109,HAP-12和GLS4)支架的新修饰。已经评估了HepAD38系统中的抗HBV活性以及每种新化合物的细胞毒性谱。其中,有五个新的
碘-和
溴-杂芳基
嘧啶类似物在低微摩尔范围内显示抗HBV活性。